Human health is being affected by various
factors which include rapid urbanization, demographic ageing and the
globalization of unhealthy lifestyles. Hypertension is one of the
keyhealth issuesthat are observed in both developed as well as
developing countries. It is a silent, invisible killer that rarely
causes symptoms and is one of the key risk factors forcoronary heart
disease and ischemic as well as hemorrhagic stroke. Hypertension can
also lead to various other problemssuch as renal impairment, visual
impairment, heart failure and retinal hemorrhage. According to the World
Health Organization (WHO), 7.5 million deaths globally are caused due
to hypertension, and it accounts to 12.8% of the total deaths.
Globally,in 2008 prevalence of hypertension was observed to be around
40% in adults aged 25. According to the National Health and Nutrition
Evaluation Survey, ithas been noted that in United States from 2007 to
2010,81.5% of the population is aware of their hypertension condition,
out of which 74% are being treated and only 52.5% are under control.
Theantihypertensive drugs market based on
the therapy area is classified into diuretics (hydrochlorothiazide and
indapamide), calcium channel blockers (nifedipine, felodipine and
diltiazem), angiotensin receptor blockers or ARBs (losartan),
angiotensin converting enzyme (ACE)inhibitors (captopril, lisinopril and
perindopril), beta blockers vasodilators (atenolol and propranolol),
alpha blockers (clonidine, guanabenz), and renin inhibitors.Diuretics
being the first line of treatment for hypertension holds the major share
of the market. All these drug classes (drugs) have shown to reduce
cardiovascular morbidity and mortality. The drugs are administered
either as a single or combined dose depending upon the stage of
hypertension, whilethe choice of drugs depends upon the patients’
medical history and current conditions.
On the basis of the geography, the
antihypertensive market can be segmented into North America, Europe,
AsiaPacific, Latin America, and Middle East and Africa.The global
antihypertensive market is dominated mainly by North America and Europe.
According to the WHO, the prevalence of hypertension is highest in
Africa and lowest in Americas. In Africa more than 40% of the adults
suffer from hypertension and many of them remain undiagnosed due to the
high cost of medications.The increased genericization by the local
companies can be a challenge for the market. Similarly, in recent years,
there has beena significant improvement in the management of
hypertension contributing to a strong decline in the death rates in
North America and Western Europe
The change in lifestyle, elevated stress
level, and rise in prevalent population, early detection and penetration
of combined dose would be the main factors to drive the growth of
antihypertensive market. The patent expiry for major drugs such as
Diovan (Novartis), Cozaar (Merck),Revatio (Pfizer), Exforge (Novartis),
Atacand (AstraZeneca), Avapro (Sanofi Aventis), BIopress(Takeda) and
Benicar (Daiichi Sankyo), along with low diagnostics rate and increased
generic penetration would result in the antihypertensive market
slowdown, but the novel antihypertensive drugs in the pipeline can
recover the losses of patent expiration.
Some of the major key players in the
global antihypertensive market includes Novartis AG, Pfizer Inc., Sanofi
S.A, Johnson & Johnson Ltd., Daiichi – Sankyo, Merck & Co.,
AstraZeneca Plc.,Ranbaxy Laboratories Limited and Lupin Limited.
No comments:
Post a Comment